Alaunos Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TCRT research report →
About the company
Alaunos Therapeutics, Inc. is an oncology company in the clinical trial phase, specializing in the creation of adoptive T-cell receptor (TCR) engineered therapies. Their pipeline includes a TCR Library, currently undergoing Phase I/II clinical trials, which comprises ten T-cell receptors designed to target mutated KRAS, TP53, and EGFR in various cancers such as non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers.
- CEO
- Holger Weis
- IPO
- 2005
- Employees
- 1
- HQ
- Houston, TX, US
Price Chart
- Market Cap
- $5.08M
- P/E
- -0.96
- P/S
- 1693.22
- P/B
- 3.15
- EV/EBITDA
- -1.15
- Div Yield
- 0.00%
- Gross Margin
- -6333.33%
- Op Margin
- -138166.63%
- Net Margin
- -136966.67%
- ROE
- -165.94%
- ROIC
- -321.82%
- Revenue
- $5.00K · -50.00%
- Net Income
- $-4,176,000 · 10.75%
- EPS
- $-2.20 · 24.66%
- Op Income
- $-4,225,000
- FCF YoY
- 40.31%
- 52W High
- $6.20
- 52W Low
- $1.67
- 50D MA
- $2.44
- 200D MA
- $2.90
- Beta
- -1.06
- Avg Volume
- 15.99K
Get TickerSpark's AI analysis on TCRT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 30, 26 | Weis Holger | other | 3,880 |
| Jun 12, 26 | Weis Holger | other | 7,761 |
| May 22, 26 | Weis Holger | other | 3,700 |
| Apr 29, 26 | Vieser Jaime | other | 6,515 |
| Apr 29, 26 | Postma Robert W | other | 6,274 |
| Apr 29, 26 | Jerman Michael Allen | other | 6,032 |
| Jan 12, 26 | Jerman Michael Allen | other | 5,406 |
| Jan 12, 26 | Postma Robert W | other | 5,622 |
| Jan 12, 26 | Vieser Jaime | other | 5,839 |
| Nov 21, 25 | Vieser Jaime | other | 5,340 |
Our TCRT coverage
Recent articles, reports, and earnings notes.
No research on TCRT yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate TCRT report →Similar companies
Peers in the same neighborhood.